First-Trimester Screening: Timing, Protocol and Counselling Considerations in Indian Practice
Quick Answer First-trimester screening for chromosomal abnormalities is optimally performed between 11+0 and 13+6 weeks of gestation. The combined screening test — NT measurement plus maternal serum free β-hCG and PAPP-A — achieves detection rates of approximately 85–90% for Down syndrome (Trisomy 21) at a 5% false-positive rate when performed within this window. NIPT (Non-Invasive Prenatal Testing) can be offered from 10 weeks onwards and carries a higher sensitivity, but does not replace diagnostic confirmation in screen-positive cases. This article covers the timing rationale, measurement standards, counselling framework, and the specific considerations that apply in Indian practice. First-trimester screening is one of the most clinically consequential steps in antenatal care — and one of the areas where clinical practice among OBGYN doctors varies most. Timing errors, suboptimal NT measurement technique, incomplete counselling, and inconsistent integration of combined screening markers are all common in routine practice, and all affect the clinical utility of the screening result. This article is a protocol-level reference. It covers the timing window and why it matters, the components of combined screening, NT measurement standards, the role of NIPT, second-line biochemical markers, and the counselling framework a practising clinician needs when delivering a screen-positive result. It also addresses the specific legal and procedural context that applies to prenatal diagnosis in India. Doctors who want structured training in prenatal screening interpretation and fetal ultrasound can explore MGA’s Fellowship in Fetal Medicine, which covers this content in depth across dedicated modules. 11–14 wk Optimal combined screening window 85–90% T21 detection rate — combined screening >99% NIPT sensitivity for T21 What this article covers Why the 11–14 week window matters — the biological rationale NT measurement — standards and common errors Combined first-trimester screening — components and interpretation NIPT — role, timing, and limitations in Indian practice Second-trimester integration — when to offer the quadruple test Screen-positive results — the counselling framework PCPNDT context — what practitioners need to know Frequently asked questions Why the 11–14 week window matters — the biological rationale The 11+0 to 13+6 week window is not arbitrary. Nuchal translucency — the fluid-filled space at the back of the fetal neck, measured on ultrasound — reaches its maximum diagnostic utility within this window. NT is physiologically present in all fetuses to a small degree, and naturally increases after 14 weeks in unaffected pregnancies as lymphatic drainage establishes. Outside this window, NT measurements are either technically not yet feasible (before 11 weeks, the fetus is too small for reliable measurement) or diagnostically unreliable (after 14 weeks, NT has already begun to resolve in normal fetuses, narrowing the gap between affected and unaffected). The CRL (crown-rump length) range within this gestational window is 45–84 mm. The CRL measurement determines whether the fetus is within the NT measurement window, not gestational age alone — this distinction matters when dates are uncertain. Practical point: When a patient presents at or near 14 weeks, do not delay referral to a better-equipped centre if your local equipment or training is not adequate for NT measurement. A NT measurement at 13+5 is still within protocol; a measurement at 14+1 is not. Missing the window means the combined test cannot be performed and the patient defaults to second-trimester screening alone, which has lower sensitivity. NT measurement — standards and common errors NT measurement is the most skill-dependent component of first-trimester screening. Poorly performed NT measurements produce unreliable risk calculations regardless of how good the serum marker results are. Measurement standards (FMF protocol) The Fetal Medicine Foundation (FMF) protocol is the widely used international standard. Key requirements: Fetal position: Sagittal section of the fetus in a neutral position — neither hyperflexed nor hyperextended. Both hyperflexion and hyperextension artificially alter the NT measurement. Image magnification: The fetal head and upper thorax should occupy the full screen. The fetus should fill at least 75% of the screen. Calipers: Placed on the inner borders of the nuchal space — not on the skin lines themselves. The horizontal part of the caliper should be barely visible against the echogenic line. Skin line vs amnion: The amniotic membrane must not be confused with the skin line. Wait for the fetus to move away from the amnion if they appear fused. Multiple measurements: Take at least three measurements and use the largest for risk calculation. Common measurement errors Error Effect on Measurement Correction Neck hyperflexion Falsely increases NT by up to 0.6 mm Reposition, wait for neutral posture Measuring on amnion, not skin Falsely increases NT Wait for fetal movement to separate amnion Calipers on outer borders Overestimates NT Use inner-to-inner caliper placement Insufficient magnification Imprecise caliper placement Head and thorax to fill >75% of screen Single measurement accepted Misses higher reproducible value Minimum 3 measurements; use the largest Combined first-trimester screening — components and interpretation Combined screening integrates three inputs into a single risk calculation for chromosomal abnormalities, primarily Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome), and Trisomy 13 (Patau syndrome). Three components 1. Maternal age-related background risk: The prior probability of chromosomal abnormality based on the mother’s age at the expected date of delivery — the starting point before any test modifies it. 2. Nuchal translucency (NT) measurement: Expressed as a multiple of the median (MoM) for that gestational age and CRL. An NT at or above the 95th centile (approximately ≥2.5 mm at 11 weeks, ≥3.5 mm at 13 weeks) raises the posterior risk substantially, though the precise risk change depends on the full calculation. 3. Maternal serum markers — free β-hCG and PAPP-A: Free β-hCG is elevated in Down syndrome pregnancies at 11–13 weeks (approximately 2.0 MoM). PAPP-A is reduced in Down syndrome pregnancies at 11–13 weeks (approximately 0.4–0.5 MoM). These two markers change in opposite directions in Trisomy 21, which is what gives the combined test its discriminatory power. Risk threshold and result interpretation The standard combined screening risk threshold for classifying a result as screen-positive is 1 in 300 (or 1:300) for Trisomy 21. Results above this threshold (e.g., 1:50, 1:120) are screen-positive;
